CompletedNCT04714359
An extension study of MDMA-assisted therapy for PTSD
About this title
Read the official source — NCT04714359Medication studyAges 18+Multiple countries
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Los Angeles and 14 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: March 8, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 87
- Sponsor
- Resilient Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, Israel
- Age range
- Over 18 Years
- Official registry ID
- NCT04714359
- Official title
Show the full official title
A Multi-Site Open-Label Safety Extension Study of Manualized MDMA-Assisted Psychotherapy for the Treatment of Participants With Posttraumatic Stress Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Los Angeles, United States · San Francisco, United States · Boulder, United States
10 more locations
- Fort Collins, United States
- New Orleans, United States
- Boston, United States
- New York, United States
- Mt. Pleasant, United States
- Madison, United States
- Vancouver, Canada
- Montreal, Canada
- Beer Yaaqov, Israel
- Tel Aviv, Israel
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Resilient Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including Midomafetamine HCl.
Who was this study for?
Listed age limits: from 18 years.
